


♥ About RAUMEDIC

As a partner of the international medical technology and pharmaceutical industry, RAUMEDIC develops and produces customized components for customers, including tubing, catheters, and molded parts as well as complex groups of components and systems for a wide range of diagnostic and therapeutic uses. For the clinical areas of neuro-monitoring and traumatology, RAUMEDIC produces high-precision pressure-measurement sensors. The company is 100 percent family-owned.



Components for medical technology



Pharma solutions



Medical device manufacturer

📄 Certifications



📊 Numbers, dates, facts



Experience

More than 70 years in the field of medical technology



Workforce

Approx. 1,000 employees worldwide



Turnover


Growth of 8 percent on average per year



REHAU Group

Guarantor for long-term partnerships

🌐 Company Structure





Management

Executive Board RAUMEDIC AG	Board of Officers RAUMEDIC INC
<p>Stefan Seuferling Chairman of the Executive Board & Chief Executive Officer (CEO)</p>	<p>Brian Hutchison President & Chief Executive Officer (CEO)</p>
<p>Thomas Knechtel Member of the Executive Board & Chief Technology Officer (CTO)</p>	<p>Christian Reinert General Counsel & Corporate Secretary</p>
<p>Martin Schenkel Member of the Executive Board & Chief Operating Officer (COO)</p>	
<p>Daniel Seibert Member of the Executive Board & Chief Financial Officer (CFO)</p>	
<p>Jürgen Werner Chairman of the Supervisory Board</p>	<p>Stefan Seuferling Chairman of the Board of Directors</p>

Portfolio




From tubing and molded parts produced with medical-grade plastics, to complex groups of components and medical products with sensor technology – thanks to the depth of its production capabilities, RAUMEDIC delivers a wide range of products to medical technology and pharmaceutical companies, as well as to clinics around the world.



Key Financial Figures (RAUMEDIC Group)


Net Sales (in millions of €)

Over the last years, net sales were growing stronger than the market.




Balance Sheet (total assets in millions of €)

Healthy balance sheet with a high equity ratio and a low debt ratio.



Investments (in millions of €)

High investment level: over the next 5 years (2021-2025) we will invest **over €100 Million** for capacity expansion.



Staff Development

Personnel increase of 25 percent over the last five years.

